YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.

Browsing by Author "Ozdogar, A.T."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Is Disease-Modifying Therapy Use in Multiple Sclerosis a Risk Factor During the Covid-19 Pandemic? a Large Cohort Study
    (Pro Medicina Foundation, 2024) Ozakbas, S.; Baba, C.; Yavas, I.; Samadzade, U.; Ozdogar, A.T.
    Objective: This study aims to investigate the relationship between disease-modifying therapies (DMTs) used in people with MS (pwMS) and the risk of COVID-19 in-fection. Methods: This longitudinal cohort study included the MS cohort of 3402 people followed for COVID-19 infection. The whole MS cohort was interviewed at least once for information about COVID-19. A semi-structured interview was developed and performed by a team consisting of a medical doctor, nurse, and physiotherapist. Clinical information was obtained from the patient's medical records. This study was approved by the Noninvasive Research Ethics Board (Date: 08.09.2021, Decision No: 2021/25-06). Results: Of the 487 pwMS infected with COVID-19, 35 reported reinfections. The major differences regarding DMT between pwMS with and without COVID-19 infection were observed for fingolimod, ocrelizumab, and azathioprine. Forty-three (8.9%) people experienced the COVID-19 infection severely or critically; 12 (37.5%) had MS treatment with ocrelizumab. Fifty percent of pwMS who were treated in intensive care (7/14 patients) and died (3/6 patients) were being treated with ocrelizumab. As a result of regression analysis, being younger and using di-methyl fumarate, fingolimod, ocrelizumab, and cladrib-ine DMTs were the main factors associated with having COVID-19 infection group. Conclusions: Current results show that disability due to MS and increased disease duration are not risk factors for COVID-19 infection, while age is negatively associated with contracting COVID-19 infection. These results show no relationship between the MS clinic and COVID-19 in-fection. We have found that using certain DMTs in pwMS increases the risk of contracting COVID-19 infection. © 2024 PRO MEDICINA Foundation,41 Published by PRO MEDICINA Foundation.
  • Thumbnail Image
    Book Part
    A Man With Multiple Sclerosis Running From Restless Legs Syndrome
    (Springer International Publishing, 2023) Kahraman, T.; Ozdogar, A.T.
    Medical treatments are in the foreground treatment of restless legs syndrome (RLS). Although the benefits of exercise have become more evident, research on exercise has not included people with multiple sclerosis (MS) and RLS. This case report examined how aerobic exercise affects RLS symptoms in a male with MS and RLS. The RLS diagnostic criteria were used to diagnose RLS. Because RLS symptoms can affect many aspects, comprehensive assessment tools were chosen. Aerobic exercise training was applied for 24 sessions with a physical therapist using a recumbent exercise bike. The sessions started with 20 min, with 2-3 min of warm-up, 15 min of loading, and 2-3 min of cool-down, and reached 30 min at the end of 12 weeks. As a result, aerobic exercise might be a promising method for improving RLS severity, sleep quality, gait, and health-related quality of life in people with MS and RLS. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2023. All rights reserved.